{"schema_version":"1","generated_at":"2026-11-08T00:45:05.643Z","data_as_of":null,"url":"https://www.findmykol.com/kol/ruth-sacks","json_url":"https://www.findmykol.com/kol/ruth-sacks/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"ruth-sacks","name":"Ruth Sacks","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"Grady Memorial Hospital","institution_url":"https://www.findmykol.com/institution/grady-memorial-hospital","city":"Atlanta","state":"GA","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1063822393","orcid":"0000-0002-7181-3135","openalex":"A5102951430"},"summary":"Ruth Sacks is a Hematology physician affiliated with Grady Memorial Hospital. OpenAlex indexes 34 publications with 224 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":34,"cited_by_count":224,"h_index":7,"latest_activity_year":2026,"source":"works"},"trials":{"count":1,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05877859","title":"Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab","status":"RECRUITING","role":"Overall official","sponsor":"Emory University","source_url":"https://clinicaltrials.gov/study/NCT05877859","trial_url":"https://www.findmykol.com/trial/NCT05877859"},{"nct":"NCT05464810","title":"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer","phase":"EARLY_PHASE1","status":"RECRUITING","role":"Overall official","sponsor":"Emory University","source_url":"https://clinicaltrials.gov/study/NCT05464810","trial_url":"https://www.findmykol.com/trial/NCT05464810"}],"source":"trials"},"payments":{"company_count":4,"program_years":{"first":2021,"last":null},"rows_total":5,"shown":3,"withheld":2,"rows":[{"payer":"BioNTech SE","program_year":2025,"amount_usd":424,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063822393"},{"payer":"Tempus AI, Inc","program_year":2025,"amount_usd":18.79,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063822393"},{"payer":"Eisai Inc.","program_year":2025,"amount_usd":15.5,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1063822393"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1063822393","source":"payments"},"publications":{"total":34,"shown":5,"withheld":29,"matched_by":"OpenAlex author record","recent":[{"title":"Socioeconomic and racial disparities in receipt of treatment among early-stage ER+/PR+ HER2- breast cancer: Insights from invasive breast cancer OncoDX recurrence score database.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.520","status":"verified"},{"title":"Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care","year":2026,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2026.02.005","status":"verified"},{"title":"Real-world outcomes of Black versus non-Hispanic White women with stage IV HER2-low breast cancer treated with trastuzumab deruxtecan at an urban academic center.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e13102","status":"verified"},{"title":"Overall survival (OS) in premenopausal ER+/PR+, HER2− breast cancer (BC) treated with endocrine therapy (ET) ± chemotherapy (CT): A National Cancer Database (NCDB) analysis.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.519","status":"verified"},{"title":"Antibody-drug conjugate (ADC) after ADC: Predicting survival in patients with HER2-low metastatic breast cancer with lung metastasis using artificial intelligence (AI) and radiomics.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1027","status":"verified"}],"source":"works"},"contact":{"address_1":"1365 CLIFTON RD NE","city":"Atlanta","state":"GA","zip":"303221013","phone":"404-251-5266","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1063822393","source":"identity"},"similar":[{"name":"Jaydevsinh Dolia","slug":"jaydevsinh-dolia","institution":"Grady Memorial Hospital","specialty":"Vascular Neurology","url":"https://www.findmykol.com/kol/jaydevsinh-dolia","json_url":"https://www.findmykol.com/kol/jaydevsinh-dolia/profile.json"},{"name":"Jonathan Grossberg","slug":"jonathan-grossberg","institution":"Grady Memorial Hospital","specialty":"Neurological Surgery","url":"https://www.findmykol.com/kol/jonathan-grossberg","json_url":"https://www.findmykol.com/kol/jonathan-grossberg/profile.json"},{"name":"Mara Schenker","slug":"mara-schenker","institution":"Grady Memorial Hospital","specialty":"Orthopaedic Trauma","url":"https://www.findmykol.com/kol/mara-schenker","json_url":"https://www.findmykol.com/kol/mara-schenker/profile.json"},{"name":"Ighovwerha Ofotokun","slug":"ighovwerha-ofotokun","institution":"Grady Memorial Hospital","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/ighovwerha-ofotokun","json_url":"https://www.findmykol.com/kol/ighovwerha-ofotokun/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"},{"name":"Jaroslaw Maciejewski","slug":"jaroslaw-maciejewski","institution":"Cleveland Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/jaroslaw-maciejewski","json_url":"https://www.findmykol.com/kol/jaroslaw-maciejewski/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":2,"publications":29}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2026-05-26","provider_certified":"2026-05-26","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}